News - Eli Lilly

Filter

Current filters:

Eli Lilly

Popular Filters

1 to 25 of 213 results

Eli Lilly 2nd-qtr sales takes hit from generics; net income falls 39%

24-07-2014

US pharma major Eli Lilly reported second quarter 2014 revenues fell 17% to $4.935 billion, reflecting…

Eli LillyFinancialPharmaceutical

UK's NICE changes guidance to recommend Eli Lilly’s Efient for blood clots

UK's NICE changes guidance to recommend Eli Lilly’s Efient for blood clots

23-07-2014

The National Institute for Health and Care Excellence (NICE), the UK’s health care guidance body, has…

Acute coronary syndromesCardio-vascularEfientEli LillyPharmaceuticalprasugrelRegulationUK

Seven pharma companies offer up compounds to UK researchers

Seven pharma companies offer up compounds to UK researchers

22-07-2014

UK researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds…

AstraZenecaEli LillyGlaxoSmithKlineJanssenMedical Research CouncilPfizerPharmaceuticalResearchTakeda PharmaceuticalUCBUK

Immunocore and Eli Lilly sign $25 million collaboration

Immunocore and Eli Lilly sign $25 million collaboration

16-07-2014

UK-based biotech firm Immunocore and US drug major Eli Lilly today announced they have entered into a…

BiotechnologyEli LillyImmunocoreImmunologyLicensingLillyOncologyUKUSA

Anthera acquires Sollpura for exocrine pancreatic insufficiency from Eli Lilly

Anthera acquires Sollpura for exocrine pancreatic insufficiency from Eli Lilly

15-07-2014

US-based biopharma company specialized in autoimmune diseases Anthera Pharmaceuticals has acquired Sollpura…

Anthera PharmaceuticalsEli LillyGastro-intestinalsLiprotamaseNon-porcine enzyme productPaul TruexSollpura

China’s Yabao Pharma partners with Eli Lilly to develop diabetes candidate

China’s Yabao Pharma partners with Eli Lilly to develop diabetes candidate

08-07-2014

Chinese drugmaker Yabao Pharmaceutical has entered a strategic partnership with US pharma major Eli Lilly…

ChinaDiabetesEli LillyLicensingPharmaceuticalYabao Pharmaceutical

UK’s NICE draft guidance recommends Lilly’s Efient

UK’s NICE draft guidance recommends Lilly’s Efient

20-06-2014

UK health care watchdog the National Institute for Health and Care Excellence (NICE) has today published…

Cardio-vascularEfientEli LillyPharmaceuticalPricingRegulationUK

Boehringer and Lilly re-file empagliflozin NDA with FDA

Boehringer and Lilly re-file empagliflozin NDA with FDA

19-06-2014

The US subsidiary of German family-owned drugmaker Boehringer Ingelheim and pharma major Eli Lilly have…

Boehringer IngelheimDiabetesEli LillyempagliflozinPharmaceuticalRegulationUSA

Are pharma apps the next big thing?

Are pharma apps the next big thing?

13-06-2014

Here's our take on the week's top stories.

Eli Lilly

Lilly’s Cyramza disappoints in Ph III liver cancer trial

Lilly’s Cyramza disappoints in Ph III liver cancer trial

12-06-2014

US drug major Eli Lilly (NYSE: LLY) says the Phase III REACH trial of Cyramza (ramucirumab) in patients…

ChemistryCyramzaEli LillyHealth Medical PharmaLillyMajorOncologyOrganic chemistryPharmaceuticalResearch

ASCO 2014 kicks off with news on lenvatinib, Cyramza, olaparib and Recentin

ASCO 2014 kicks off with news on lenvatinib, Cyramza, olaparib and Recentin

01-06-2014

The 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) began on Friday in Chicago,…

AstraZenecaBiotechnologyCyramzaEisaiEli LillylenvatinibolaparibOncologyRecentinResearch

Boehringer and Lilly’s diabetes drug Jardiance gains EU approval

23-05-2014

German family-owned pharma major Boehringer Ingelheim and US partner Eli Lilly have received Marketing…

Boehringer IngelheimDiabetesEli LillyempagliflozinEuropeJardiancePharmaceuticalRegulation

Lilly loses out in UK Alimta vitamin dosage regimen patent law suit

16-05-2014

US pharma major Eli Lilly says that the English High Court has determined that the vitamin dosage regimen…

ActavisAlimtaEli LillyGenericsLegalOncologyPatentsUK

Mylan debuts generic Zyprexa Zydis in USA; Actavis Exalgo copy approved

Mylan debuts generic Zyprexa Zydis in USA; Actavis Exalgo copy approved

14-05-2014

US generic drugmaker Mylan says it has launched Olanzapine Orally Disintegrating tablets (ODT), 5mg,…

ActavisEli LillyExalgoGenericsMallinckrodtMarkets & MarketingMylanNeurologicalRegulationUSAZyprexa

Lilly's basal insulin peglispro beats insulin glargine in HbA1c reduction for type 2 diabetes

Lilly's basal insulin peglispro beats insulin glargine in HbA1c reduction for type 2 diabetes

13-05-2014

US pharma major Eli Lilly has released positive top-line results of three completed Phase III clinical…

DiabetesEli LillyLantuspeglisproPharmaceuticalResearchSanofi

Lilly to appeal $450 million fine in Brazil labor case

Lilly to appeal $450 million fine in Brazil labor case

10-05-2014

US drug major Eli Lilly revealed on Friday that the 2nd Circuit of the Labor Court of Paulinia in the…

BrazilEli LillyLegalPharmaceuticalProduction

Eli Lilly 1st-qtr 2014 net income plunges, sales down, hit by generic competition

24-04-2014

US pharma major Eli Lilly posted first-quarter 2014 financial results, with revenue declined 16 % to…

Eli LillyFinancialPharmaceutical

Lilly's Cyramza first FDA-approved drug for advanced gastric cancer after prior chemo

22-04-2014

The US Food and Drug Administration has approved pharma major Eli Lilly’s Cyramza (ramucirumab) as…

CyramzaEli LillyNorth AmericaOncologyPharmaceuticalRegulationUSA

Novartis swaps products with GlaxoSmithKline, sells unit to Lilly

Novartis swaps products with GlaxoSmithKline, sells unit to Lilly

22-04-2014

In what looks like a significant restructuring of company focuses, Swiss drug major Novartis and UK peer…

Eli LillyGlaxoSmithKlineMergers & AcquisitionsNovartisPharmaceuticalVaccines

1 to 25 of 213 results

Back to top